Article

A Pooled Analysis of Continued Prophylactic Efficacy of Quadrivalent Human Papillomavirus (Types 6/11/16/18) Vaccine against High-grade Cervical and External Genital Lesions

Department of Virus, Hormones and Cancer, Institute of Cancer Epidemiology, Danish Cancer Society/Rigshospitalet, Copenhagen, Denmark.
Cancer Prevention Research (Impact Factor: 5.27). 10/2009; 2(10):868-78. DOI: 10.1158/1940-6207.CAPR-09-0031
Source: PubMed

ABSTRACT Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection from HPV 6/11/16/18-related cervical, vaginal, and vulvar disease through 3 years. We provide an update on the efficacy of the quadrivalent HPV vaccine against high-grade cervical, vaginal, and vulvar lesions based on end-of-study data from three clinical trials. Additionally, we stratify vaccine efficacy by several baseline characteristics, including age, smoking status, and Papanicolaou (Pap) test results. A total of 18,174 females ages 16 to 26 years were randomized and allocated into one of three clinical trials (protocols 007, 013, and 015). Vaccine or placebo was given at baseline, month 2, and month 6. Pap testing was conducted at regular intervals. Cervical and anogenital swabs were collected for HPV DNA testing. Examination for the presence of vulvar and vaginal lesions was also done. Endpoints included high-grade cervical, vulvar, or vaginal lesions (CIN 2/3, VIN 2/3, or VaIN 2/3). Mean follow-up time was 42 months post dose 1. Vaccine efficacy against HPV 6/11/16/18-related high-grade cervical lesions in the per-protocol and intention-to-treat populations was 98.2% [95% confidence interval (95% CI), 93.3-99.8] and 51.5% (95% CI, 40.6-60.6), respectively. Vaccine efficacy against HPV 6/11/16/18-related high-grade vulvar and vaginal lesions in the per-protocol and intention-to-treat populations was 100.0% (95% CI, 82.6-100.0) and 79.0% (95% CI, 56.4-91.0), respectively. Efficacy in the intention-to-treat population tended to be lower in older women, women with more partners, and women with abnormal Pap test results. The efficacy of quadrivalent HPV vaccine against high-grade cervical and external anogenital neoplasia remains high through 42 months post vaccination.

Download full-text

Full-text

Available from: Elmar A Joura, Aug 29, 2015
0 Followers
 · 
208 Views
  • Source
    • "These vaccines protect against HPV types 16 and 18 (Cervarix) and HPV types 6, 11, 16, and 18 (Gardasil). Both vaccines are highly effective against HPV 16/18, and Gardasil has shown greater than 98% efficacy against HPV 6/11-associated genital warts [6–8]. Although these vaccines will likely reduce the incidence of HPV-associated diseases in the long-term, they do not protect against the other high-risk HPV types and are ineffective at treating established infections [9,10]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The human papillomavirus (HPV) vaccines effectively protect against new infections of up to four HPV subtypes. However, these vaccines are not protective against many other clinically relevant HPV subtypes and are ineffective at treating established HPV infections. There is therefore a significant need for antiviral treatments for persistent HPV infections. A promising anti-HPV drug target is the interaction between the HPV E2 protein and cellular bromodomain-containing protein 4 (Brd4) since this protein complex mediates several processes important for the viral life cycle including viral genome maintenance, replication, and transcription. Using bimolecular fluorescence complementation (BiFC) technology, we demonstrate the E2 and Brd4 interaction on both interphase chromatin and mitotic chromosomes throughout mitosis. The E2-Brd4 BiFC was significantly diminished by mutating the Brd4 binding sites in E2 or by a dominant negative inhibitor of the E2-Brd4 interaction, demonstrating the potential of BiFC for identifying inhibitors of this important virus-host interaction. Importantly, when Brd4 was released from chromatin using the bromodomain inhibitor JQ1(+), the E2-Brd4 interacting complex relocated into foci that no longer associate with mitotic chromosomes, pointing to JQ1(+) as a promising antiviral inhibitor of HPV genome maintenance during HPV persistent infection.
    PLoS ONE 10/2013; 8(10):e77994. DOI:10.1371/journal.pone.0077994 · 3.23 Impact Factor
  • Source
    • "Vaccination also provided high protection for the TVC group, which includes individuals previously exposed to HPV, against HPV16/18 type associated CIN2 (>54.8%), CIN3 (>45.1%) and AIS (>60%) [7,8,10] (Table 2). HPV vaccination is highly efficient at reducing both HPV 16/18 and associated pre-cancerous lesions, particularly when given to a HPV naïve population such as that targeted by mass vaccination programs. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Since the introduction of the HPV vaccine, questions have been asked about its efficacy in preventing cancer linked with HPV. Concerns about the HPV vaccine safety profile have also been raised. This paper highlights the rapidly growing body of evidence (including clinical trials and post-marketing surveillance) illustrating both the safety of the HPV vaccine, through a detailed investigation of reported adverse events, and its efficacy in reducing both HPV infections rates and the resulting drop in cervical lesions, which have been demonstrated to be good predictors of cervical cancer risk.
    Infectious Agents and Cancer 06/2013; 8(1):22. DOI:10.1186/1750-9378-8-22 · 2.07 Impact Factor
  • Source
    • "For the bivalent vaccine, efficiency for prevention of HPV-16/18-related cervical intraepithelial neoplasia (CIN) was 98% [Paavonen et al. 2009]. For the quadrivalent vaccine , the efficacy for CIN was 100% for all four HPV subtypes, in addition to a 98.9% reported efficacy for prevention of HPV-6/11/16/18-related genital warts, and 100% efficacy for HPV-16/18- related vulval and vaginal intraepithelial neoplasia [Kjaer et al. 2009; Munoz et al. 2009]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The outcome of penile cancer is proportional to the stage at presentation. Strategies aimed at primary prevention would have a clear advantage, both for the individual and in terms of health economics. A number of preventative measures could be employed, including circumcision, smoking cessation, education on hygiene and human papillomavirus (HPV) prevention. There is a high prevalence of HPV infection associated with penile cancer worldwide. The recent development of HPV vaccines has facilitated interest in their use for the prevention of penile cancer. In this article we review the literature surrounding penile cancer prevention and HPV vaccination in men.
    Therapeutic Advances in Urology 06/2013; 5(3):161-9. DOI:10.1177/1756287212465456
Show more